Merck Marches Keytruda Into Next Wave Of Indications
This article was originally published in The Pink Sheet Daily
Executive Summary
ASCO is jumping off point as the company looks beyond melanoma and lung cancer to the next wave of potential cancer indications for its PD-1 inhibitor Keytruda, initiating pivotal trials in head & neck cancer and colorectal cancer.